Drugs / CORT125329
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04672512 | Oct 2020 → Jan 2022 | — | Corcept Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CORT125329 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04672512 ↗ |
| Route | Oral | “CORT125329 lipid capsule formulation 1 or 2 for oral administration” NCT04672512 ↗ |